Web Exclusives

In Latin American countries, the onset of breast cancer is approximately 10 years earlier than in high-income countries. Moreover, the incidence rate of breast cancer in individuals aged <40 years is close to 11%, which is higher than the rates in developed regions such as the United States and the European Union. Additionally, most of these young women are diagnosed with advanced-stage disease. Read More ›

A growing body of research has demonstrated that 5 to 10 years of adjuvant endocrine therapy (ET) plus ovarian function suppression (OFS) in patients with estrogen receptor (ER)-positive breast cancer reduces disease recurrence and mortality. However, despite this proven benefit, adverse events (AEs) associated with ET plus OFS may have a negative impact on patients’ quality of life. Read More ›

In addition to the consideration of patient age, treatment selection for advanced breast cancer should include consideration of disease characteristics as outlined in evidence-based guidelines. Read More ›

The Young Survival Coalition (YSC) is a nonprofit patient advocacy organization in the United States that supports approximately 250,000 patients diagnosed with breast cancer before the age of 40 years. Read More ›

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results from the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values. Read More ›

A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer. Read More ›

Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials. Read More ›

A recently released study found a significant concordance rate drop between liquid and tissue biopsies via next-generation sequencing when patients had disease progression. Read More ›

A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation. Read More ›

Page 2 of 61

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: